RxDoctor Payments Data

Gail Bodner, MD

Family Medicine · Lancaster, PANPI 1720139090

Payments from drug & device makers

$4,081in general payments, 2019–2025

Across 270 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$781
  • AstraZeneca$674
  • AbbVie$554
  • Lilly USA, LLC$416
  • Amarin Pharma, Inc.$402
  • GSK$288
  • plus $966 from 21 others

What the payments were for

  • Food & beverage$4,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,081 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,038
Medicare patients
35
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$74,583
TrulicityDulaglutide21$40,190
EliquisApixaban18$30,435
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,665
MounjaroTirzepatide17$25,101
JardianceEmpagliflozin17$21,309
RexultiBrexpiprazole11$15,624
VascepaIcosapent Ethyl28$15,489
LinzessLinaclotide16$11,968
Breo ElliptaFluticasone/Vilanterol18$10,222
SymbicortBudesonide/Formoterol Fumarate16$4,217
Icosapent Ethyl15$3,492
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,807
Atorvastatin Calcium172$1,616
Rosuvastatin Calcium87$1,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$781$74,58337 claims
Lilly USA, LLCTrulicity, Mounjaro$416$65,29138 claims
GSKTrelegy Ellipta, Breo Ellipta$288$35,88740 claims
PfizerEliquis$129$30,43518 claims
Boehringer IngelheimJardiance$15$21,30917 claims
Otsuka America Pharmaceutical, Inc.Rexulti$27$15,62411 claims
AbbVieLinzess$554$11,96816 claims
AstraZenecaSymbicort$674$4,21716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →